[EN] COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA TOLÉRANCE AUX ANTIBIOTIQUES
申请人:GEN HOSPITAL CORP
公开号:WO2014176258A1
公开(公告)日:2014-10-30
The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.
Photocatalytic Generation of 2-Azolyl Radicals: Intermediates for the Azolylation of Arenes and Heteroarenes via C–H Functionalization
作者:Amandeep Arora、Jimmie D. Weaver
DOI:10.1021/acs.orglett.6b01718
日期:2016.8.19
2-bromoazoles via photocatalysis, is a powerful intermediate for the intermolecular arylation of unmodified (hetero)arenes. The reaction is characterized by mild conditions, operational simplicity, tolerance toward functional and sterically demanding groups, broad scope, and anti-Minisci selectivity. A working mechanism is provided, and a low-solubility amine is essential for successful coupling. The utility
COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS
申请人:THE GENERAL HOSPITAL CORPORATION
公开号:US20160052890A1
公开(公告)日:2016-02-25
The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of
Pseudomonas aeruginosa.
Methods of treating bacterial infections in a patient, including
Pseudomonas aeruginosa
infections, are also provided by the disclosure.